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In diagnosis of disease, one of the most crucial tools is a tissue biopsy of the afflicted area. Specifically, a 
minimally invasive needle biopsy can provide a Nephrologist with a kidney tissue specimen containing 
cells that can be examined under microscope to aid in diagnosis of the kidney diseases. As with all 
medical procedures, there are risks to the biopsy procedure that the Nephrologist must weigh prior to 
performing a biopsy. One risk of the kidney biopsy is a bleed from the biopsy site. In practice, bleeding 
occurs in approximately one third of patients with normal clotting factors. The severity of the bleed 
dictates the course of treatment for the patient. Remedies for the bleed may range from attempting to pack 
the biopsy site with hemostatic agents to blood transfusions to nephrectomy and in rare cases the bleeding 
is so severe that death occurs. 
 
To improve patient and biopsy procedure safety, Dr. William Weitzel of the Nephrology department of 
the University of Michigan Health System has proposed that a biopsy needle be developed that is capable 
of stopping a bleed at the biopsy site. Furthermore, he has recommended that the use of a hemostatic 
agent be the method through which bleeding is controlled.  
 
The performance of our device was benchmarked against the current biopsy device used, call the BARD 
Monopty®. We will need a tissue sample volume of 9mm3and needle velocities of 0.9m/s. Additionally, 
our device must deliver a means of stopping a bleed for repeated biopsies without greatly altering current 
biopsy practice. The prototype will be an experimental device, to be used strictly in a lab setting. The 
purpose is not to build a device which is ready to be deployed into the field, but one that will help 
determine whether or not the approach of deploying hemostatic at the site of the biopsy is a reliable way 
to reduce bleeding. Using these engineering specifications and the requirement provided by Dr. Weitzel, 
various concepts were derived using a functional decomposition. These concepts were then analyzed 
using a Pugh chart to determine the best concept, which was then modified to become the alpha design. 
 
The final design uses a similar concept as the BARD Monopty® device, with an inner needle firing first, 
then an outer sheath firing and cutting and securing a piece of tissue in a cavity in the inner needle. A 
third stage has been added to deliver a hemostatic through a groove on the opposite side of the inner 
needle as the cavity, through which a liquid hemostatic will travel. The hemostatic will be deployed at the 
site of the biopsy. This device will enable the user to alter the amount of hemostatic that is delivered in 
order to collect as much data as possible regarding the effectiveness of the device. 
 
After manufacturing was finished, one sub-component of the device did not work as planed (the clips in 
the firing mechanism of the needles). Therefore, we were unable to test it using the laboratory setup that 
we had created as planned. However, we were able to prove that all other sub components of the device 
functioned properly. Additionally, we were able to get a large enough sample of tissue, and were able to 
prove that our needle design enabled hemostatic to flow to the hemostatic site.  
 
A thorough discussion of challenges with the project along with specific project recommendations are 
given to best present how further work on this project should be carried out. We thoroughly evaluated 
every aspect of the project to provide our best hind sight on how to make a vastly more successful product 
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Nephrology, derived from the Greek word “nephros,” meaning kidney, is the study of kidneys. In the 
medical field, nephrology is a specialty within the field of internal medicine. This specialty focuses on 
diseases of the kidney and how to diagnose and treat those diseases. A biopsy is a common tool used in 
the diagnosis of disease. A biopsy is the collection of tissue cells from a site for the purpose of 
examination.  In the case of renal disease, the percutaneous biopsy, or needle biopsy, is a common way to 
procure tissue cells from the kidney. In a renal biopsy, the cells are collected from the cortex of the 
kidney. As shown in Figure 1, the cortex has an extensive vascular structure and thus there is a potential 
for bleeding if some of these structures are cut during the biopsy procedure. The actual method of taking a 
biopsy today is to use ultrasonogaphy to guide the biopsy needle to the renal biopsy site while the patient 
lies in a prone position. 
 
 
Figure 1: Anatomy of Kidney 
 
Unfortunately, approximately 30% of renal biopsies have bleeding complications. The treatment of these 
bleeds ranges from applying hemostatic agents, to blood transfusions, to even open surgery depending on 
the severity of the bleed. The complications can range from the patient developing hematomas, as shown 
in Figure 2, around the kidney, to hematuria, a nephrectomy, or in rare cases patient death. With this 
complication rate, doctors must weigh the risks of the procedure with the benefits of the information it 
may yield. Thus, it is desirable to look for a method to prevent bleeding at the biopsy site at the time of 





Figure 2: Renal Hematoma 
 
Dr. William Weitzel M.D. and Dr. Grant Kruger of the University of Michigan have sponsored this 
project’s effort to address bleeding complications resulting from the renal needle biopsy procedure. The 
goal of this design process is to develop a biopsy needle that can mitigate potential bleeding 
complications at the biopsy site without altering common medical practice. 
 
This project will develop a novel biopsy needle device for the kidney that adds a third stage to the 
standard biopsy process - deploying a hemostatic agent to control bleeding at the site of the biopsy. 
Through consultations with Dr. Weitzel and Dr. Kruger, the formation of a set of customer requirements 
upon which to base the design were established. These requirements are listed below as well as 
summarized in Table 1. In the table, each requirement has been weight ranked to differentiate the 
importance of each of the requirements. The weight is rated on a scale from one to ten, with ten being the 
most important. This device will be meant to be used in an experimental setting to determine if deploying 
a hemostatic is a useful way to prevent internal bleeding. Therefore the device will have much more 
adjustability for the user to find the ideal operating conditions.  
 
Table 1: Customer Requirements ranked in order of importance 
Customer Requirement  Weight 
Stopping internal bleeding  10 
Similar needle size to Bard® device  9 
Reusability and Adjustability  9 
Reliability (testable prototype)  8 
Sterility and bio-compatibility  7 
Single hand operation  6 
Fast assembly of hemostatic agent  5 
Fast retraction of needle out of kidney  3 
Lightweight  3 




Stop internal bleeding:  The most important customer requirement is to stop internal bleeding at the site 
of the biopsy once the needle has been removed. One way to accomplish this is to add a third stage to the 
current biopsy process and deploy a hemostatic agent once the outer cutting needle has come down and 
secured the tissue sample in the collection site. This hemostatic agent will be some type of liquid chosen 
for its physical and medical properties. 
 
Similar needle size to Bard device:  The needle must not exceed the outer diameter of the current Bard® 
Monopty® biopsy device, the current industry standard of kidney biopsies. The Bard® needle is already 
very thick, with an outer diameter of 1.6mm. The needle design will therefore have a maximum outer 
diameter of 1.6mm so that it is an easy transition into medical practice and no extra precautions will need 
to be taken as a result of a larger needle.  
 
Reusability and Adjustability:  In order for the new design to be easily adopted into medical practice, 
and more importantly, be able to get conclusive data from testing, one device will have to be used 
multiple times in quick succession. Thus, the ability to reload the hemostatic agent and reload the firing 
mechanism will be crucial. On top of being able to be fired multiple times, it will be important to be able 
to alter the amount of hemostatic that is fired each time in order to be able to collect data that shows what 
the ideal amount is. Because this method of stopping internal bleeding is largely undocumented, it will be 
important to be able to adjust the settings of the device in order to optimize performance. 
 
Reliability: Although a very broad requirement, reliability will be important in order to collect a 
conclusive set of data which shows whether or not the new device accomplishes a reduced probability of 
internal bleeding. Reliability will also be important for the device to be adopted into medical practice, as 
it is obvious that an unreliable device cannot be used on patients.  
 
Sterility and bio-compatibility: The new device will need to be made of materials which can be 
completely sterilized and are bio-compatible (the body will not react to a bio-compatible material). 
Although it is not completely necessary to have a sterile prototype with which to conduct tests on animal 
kidneys, the device will need to be able to be sterilized in order to be used in medical practice. 
 
Single hand operation:  In today’s practice, doctors usually operate the biopsy device with one hand 
while simultaneously operating an ultrasound machine to locate the surface of the kidney in order to hit 
the cortex of the kidney in the correct location (in an effort to reduce the chance of internal bleeding). It is 
for this reason that it is important to design a device that can be operated at full capacity with only one 
hand; there will not need to be a change in practice in order for the device to be adopted by today’s 
doctors.  
 
Fast assembly of hemostatic agent: In order to be able to use the device multiple times, it will be 
necessary to be able to load the hemostatic agent quickly and efficiently into the needle. This will make it 
possible to use the new device in the same way that current biopsy devices are being used today; one 
needle is used three or four times in quick succession.  
 
Fast retraction of the needle out of the kidney: Once the biopsy needle has been fired into the kidney, it 
is helpful to quickly remove it since the kidney moves relative to the body due to respiration. This could 
lead to unnecessary damage to the kidney, but this issue will not be at the forefront of the design process 
because it is not understood enough to take precedence over other important problems mentioned above. 
 
Lightweight: In order for the new device to be easily accepted into medical practice, it cannot be 
overwhelmingly heavy. Therefore, an effort to keep the weight of the device reasonable (under one 
kilograms) will be made. Due to the long list of problems that need to be addressed, this requirement will 
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be considered, but it is possible that the prototype will not meet it because of the difference between 
prototyping materials and production materials.  
 
Low cost:  Although it will be difficult to estimate the precise cost of a new mass produced device, an 
effort will be made to avoid unnecessary expense and favor lower cost solutions. However, a more 
expensive solution which produces superior results for the above requirements will be chosen over a low 
cost solution with inferior performance.  
 
 
2.0 INFORMATION SOURCES 
 
To design an advanced biopsy needle with bleeding control poses many unique challenges. These 
challenges fall into two major categories. The first category is technical challenges. Technical challenges 
arise from trying to achieve the engineering specifications. These challenges may be in conflict with each 
other so design optimization may be required. These challenges are often overcome by creative design 
and innovation and by also applying engineering practices to the problem at hand.  
 
The second category is device-patient interactions. These challenges prove much more difficult to 
describe as they often have many variables and are poorly understood. For example, to determine needle 
dynamics the fact that tissue is heterogeneous and visco-elastic must be considered. Optimal needle tip 
and cutter geometries must be considered. The amount of local force required to cut the tissue should be 
determined. How much needle bending occurs and how that relates to friction within the needle must be 
asked. Determining the proper hemostatic and volume of that hemostatic is unknown. As a consequence 
there are two options in addressing these questions. A series of experiments to estimate these values using 
arbitrary design elements can be performed. The second option is to recognize that the current device 
works for taking a biopsy. Taking the latter route and benchmarking the current device allows us to have 
a high level of confidence that the device will work. This allows the designing process to move forward 
and permits optimization of the device as there will be better data supporting the design changes. In terms 
of what hemostatic, it is dependent on how the patient bleeds and risks associated with each method of 
hemostasis. Here again studies can shed light for the subject on the initial design and then be included in 
subsequent design iterations. Thus, it was chosen to benchmark the current Bard device to develop the 
basic engineering specifications. 
 
To address what hemostatic to use Dr Weitzel voiced his concerns regarding types of hemostatic agents. 
In summary he asked to either use a solid, or a solid with a pro coagulant or the thickest flowable 
hemostatic. There are a myriad of hemostatic agents on the market today, and there are risks associated 
with them all. To address this problem we contacted Dr. Chris Sonnenday, an abdominal transplant 
surgeon at UMHS. He recommended that we use SURGIFLO or Gelfoam with topical thrombin to 
achieve hemostasis as they are both techniques used in the operating room at the hospital. 
 
A technical challenge that we have been investigating is the manufacturing of the prototype since the 
scale of the project is quite small. A variety of processes to achieve the desired design dimensions have 
been investigated. The expertise of Bob Coury, Roland Chen, and other faculty and staff at the university 
to obtain possible manufacturing methods of the needles for the project has been requested. 
 
 
3.0 ENGINEERING SPECIFICATIONS 
 
The engineering specifications are imperative in helping to design the Alpha prototype. To determine 
engineering specifications in a well defined and quantitative manner, thorough literature research, 
interviews with couple of doctors, and experimental testing on the BARD device. Most of the engineering 
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specifications determined are benchmarked against the BARD device have been done. The engineering 
specifications are also mapped up from the customer requirements and can be seen in appendix D. The 
engineering specifications are needle dimensions/geometry, mass of device, friction between needle and 
tissue, needle stiffness, spring constant, volume of hemostatic agent needed, volume of tissue collecting 
site, and velocity of the outer needle. 
 
Needle Dimensions and Geometry: The needle geometry is rated the most important engineering 
specification in the QFD. It will determine the amount of force needed in cutting the kidney tissue, 
effectiveness in delivering the hemostatic agent, the injuries caused on the kidney and volume of tissue 
collected. Since it is rated the most important feature, most of the design focus is given to this feature. 
However, given the limited time to produce a prototype, the decision was to have the same outer needle 
geometry as the BARD needle. This decision is based on multiple experiments on kidney-like ballistics 
gel in the lab. Good shearing from the mechanism of the ballistics gel during experiment was observed. 
Also, from the customer requirements, designing a needle that has a larger needle diameter than the 
BARD device was unacceptable. The geometry and dimensions of the BARD needle are measured using 
a certified caliper.  
 
Friction between Needle and Tissue: Due to the complexity in determining the friction between needle 
and tissue and the variation of tissue between humans, the team has decided to get an overall tissue 
friction based on experimental result done by a masters’ student in Mechanical Engineering, Mainak 
Mitra. This number will help the team in determining the optimized force to fire the outer needle for 
cutting the kidney tissue. 
  
Needle Stiffness: Needle stiffness is another factor in determining the force required to fire the outer 
needle. It depends on the material property and is quantified in the Young’s Modulus. If a soft needle is 
inserted in the kidney, the deflection of the needle will injure the surrounding kidney tissue and prolong 
the time in performing biopsy. Based on this, the decision was to design the needle out of metal. A lower 
limit of 180GPa is desired in this case. The new needle will have the same second moment of inertia as 
the BARD device at its weakest point, the tissue collection site. 
 
Spring Constant: The spring constant determines the force actuated on the outer needle. The force 
actuated is proportional to the spring constant and to the distance of spring compressed. Depending on the 
amount of space available for the spring to be compressed, the spring constant could vary. However, it 
should not be too large or too small until it affects the dimensions of the handle. 
 
Volume of Hemostatic Agent: The hemostatic agent needed depends on the tissue displaced during the 
insertion of outer and inner needle in the kidney. Depending on how far the operator placed the first 
position of the inner needle, the volume of tissue displaced in the kidney would vary. Thus, it is better for 
a design of the mechanism that can manipulate the amount of hemostatic agent accordingly. It was 
determined that the function of the volume of hemostatic agent needed to be 2.14y where y is the distance 
travelled by the needle. This calculation can be found in the Appendix D.  
 
Volume of Tissue Collecting Site: The volume of the tissue collection site needs to be at least 
9.012mm3. This result is based on the calculation done on the BARD device. The decision was to go not 
less than that value after speaking with Dr. Weitzel. A lower volume collecting site might cause the 
operator to perform the biopsy twice due to insufficient tissue samples collected and it is obviously not 
preferable. The calculation of this value can be found in the Appendix E. 
 
Velocity of the Outer Needle: The velocity profile of the outer needle was obtained after speaking with 
Mainak Mitra. The maximum velocity of the BARD device is 0.87m/s. This value will determine the 
tissue cutting mechanics. Again, the decision was to have the similar velocity profile to the BARD device 
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after looking at the satisfying results of the BARD device. Figure 3 shows the graphs which were used to 
get the velocity data. 
 
Figure 3: Data used to find desired needle velocities 
 
 
4.0 CONCEPT GENERATION 
 
In order to generate an Alpha concept, the decision was to make a functional decomposition chart to help 
identify the key functions and sub-functions that the biopsy device must accomplish. This exercise, along 
with thorough brainstorming was the main technique used to generate a variety of concepts ranging in all 
aspects of price, feasibility, and conventionality. The purpose of this section is to walk through the 
process in detail and describe some of the main concepts that were considered.  
 
Functional Decomposition – Figure 4 shows the result of the functional decomposition exercise. The 
functional decomposition was important because it helped identify the inputs that went into the biopsy 





   
Figure 4: Functional Decomposition Chart 
 
From this figure, it is easy to see that the main functions of the biopsy device are to remove tissue from 
the kidney, and to deploy a hemostatic agent at the sight of the biopsy. While these two functions were 
obvious from the start of the project, the sub-functions and the inputs were not as trivial and are much 
easier to see after having gone through the process of the functional development. 
 
The inputs for the whole device are the patient (and specifically the kidney and the surrounding tissue), 
the actions of the doctor, the stored energy in the device, and the hemostatic agent. These inputs were 
identified in the problem definition portion of the project. While all of these inputs need to be considered 
for the hemostatic deployment function, the hemostatic agent input is not important for the tissue removal 
function of the device.  
 
The sub-functions are where the real brainstorming took place. For this part of the concept generation, the 
main functions were broken down into simpler functions that involved a portion of the desired inputs and 
outputs. The first sub-function of the tissue removal is a firing of the inner needle. This sub-function will 
get tissue into the main cavity of the needle (which a sub-function of the inner needle firing). The 
following sub-function of tissue removal is the outer needle firing, which will cut the tissue that is in the 
cavity and secure it in place when the needle is removed. During this, while this sub-function is 
happening, it is important that the doctor get some feedback that the outer needle had fired so that there is 
some confirmation that the tissue is secure in the needle cavity. The last sub-function of the tissue 
removal is the positioning and removal of the needle in and out of the kidney. This sub-function is 
important to insure that the biopsy has been taken in the correct location of the kidney (the cortex), and 
that the needle is removed quickly to lessen the risk of unnecessary tissue tearing.  
 
Deployment of the hemostatic agent also has a few sub-functions associated with it. In order for the 
hemostatic to be deployed at the site of the biopsy, the agent must be stored somewhere in the device. 
Therefore, a hemostatic storage function is necessary in the device. A sub-function of this sub-function is 
the load of the hemostatic agent into the storage area of the device. This is important in order for the 
device to be used multiple times in a single procedure. The other sub-function of hemostatic deployment 
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is a delivery mechanism for the hemostatic agent. In order to get the agent at the site of the biopsy, there 
must be some method of getting the agent out of the device and into the kidney. A helpful sub-function of 
this sub-function would be some sort of feedback that the hemostatic agent has been delivered.  
 
Using the information derived from the functional development, a few main concepts were derived. These 
concepts are illustrated and discussed in the following sections. Each concept was made to focus on some 
or all of the functions and sub-functions from the functional development; some with more success than 
others. All of the original concepts can be found in the appendix.  
 
4.1 Concept 1 - Rotating Needles: The rotating needles concept is based on using a liquid hemostatic 
agent which is pre-loaded in the needle before the procedure begins. The entire needle assembly is 
inserted in the kidney, with the cavity for tissue already exposed. The doctor then releases the outer 
needle which cuts the tissue, then releases the hemostatic through a channel in the inner needle. Figure 5 
below shows needle assembly, with the inner needle showed as dashed lines. The outer needle would 




Figure 5: Rotating Needle Concept 
 
A major advantage of this method is that it allows for a more precise location of the biopsy, because the 
needles are staying in place during the entire process, so there will be no unexpected bleeding if the 
needles start in the cortex of the kidney. However, rotating needles would be a completely new concept 
for the medical community and would not be easily accepted into medical practice. Also, as is discussed 
in the following concept, a channel through the inner needle is very impractical.   
 
4.2 Concept 2 - Channel through inner needles: This concept is based on using a liquid hemostatic and 
deploying it through a channel which goes through the inner needle. It uses the same cutting mechanics 
and needle motion as the Bard device, with similar spring loaded needles. The doctor places the needles 
just outside the cortex of the kidney, fires the needles to collect the tissue sample, and then deploys the 




Figure 6: Channel through the inner needles 
 
One of the advantages of this is that it does not alter the current medical practice at all. The procedure 
would be almost identical to what is currently being done. It would also be very easy to reload the needle 
for multiple uses. However, because of this channel to deploy the liquid hemostatic is there, the cavity for 
tissue must be shallower, and therefore longer to collect an adequate sample volume. It is also extremely 




4.3 Concept 3 - Channel in needles: This concept is similar to concept 2 expect that instead of the 
channel being through the inner needle, it is simply ground into the inner needle and outer needle, so it 
looks more like a groove in both needles than a through hole in the inner needle. The figure below shows 
the channel at the bottom of the inner needle. This channel would be used to push a liquid hemostatic 
down the channel and into the biopsy sight once the outer needle has fired and cut the tissue sample from 
the kidney. In the figure below, the channels in the inner and outer needles are visible. In both this 
concept and concept 2, the hemostatic would be stored in the handheld section of the device. 
 
 
Figure 7: Channel in Needles 
 
One of the advantages of this design is that, as in concept 2, it does not alter medical practice and makes it 
easy to deploy liquid hemostatic at the site of the biopsy. This concept would also be much easier to 
machine than concept two while leaving the possibility of a large cavity size for the tissue. However, 
there are a few drawbacks: it is still difficult to machine a groove in the inner needle, and even more 
difficult to machine a groove on the inside of the outer needle.  
 
4.4 Concept 4 - Cavity for solid hemostatic agent: This concept is based on using a solid hemostatic 
agent, which is preloaded in the needles prior to each use of the device. A channel in the inner needle 
makes way for a protrusion in the outer needle to push out the hemostatic once the inner needle has been 
fired, and the outer needle fires after. The figure below illustrates the concept, showing the two needle 
assembly on the left and a cross section of the outer needle on the right side. 
 
 
Figure 8: Cavity for solid hemostatic agent 
 
The main advantage of this design is that is uses a solid hemostatic, like GELFOAM, which can not only 
stop bleeding with a clotting agent, but also stop bleeding mechanically by simply clogging the hole that 
the biopsy leaves behind. However, machining the outer needle would be very difficult, and deploying the 
hemostatic before the cutting of the tissue would not work with certainty. Another disadvantage is that it 
would be very hard to reload the solid hemostatic in between each use, making the device unlikely to be 




4.5 Concept 5 - Removable inner needle: The removable inner needle concept aims to provide use with 
the maximum space possible to deliver the hemostatic to the biopsy site. The uniqueness of this idea is to 
use the outer needle as the delivery pathway to the biopsy site. This concept most often takes the form of 
a gun bolt mechanism. In theory, the inner and outer needle would start in the loaded position. Then, the 
user would trigger the inner needle into the kidney, and the motion of the inner needle would trigger the 
outer needle to close into place just as the BARD device does. Next, the inner needle would rotate 180 
degrees to keep the specimen in the biopsy device, and the inner needle would retract further back along 
the length of the device.  
 
As the needle retracted past a given point the hemostatic could be introduced into the “barrel” of the 
device through a “breach.” Depending on the type of hemostatic chosen the inner needle could then return 
down the “barrel” of the device to push a solid hemostatic into the outer needle as the outer needle 
retracts. The inner needle could remain out of the outer needle and a liquid hemostatic could be deployed 
down the “barrel”.  
 
Drawing this concept proves difficult as it is more sequence driven than packaging or geometry driven. It 
is best to think of this concept as that of a rifle; the inner needle as the bolt, the hemostatic entry point as 
the breach, and the outer needle as an “elongating and retracting” barrel. This concept focuses more on 
the design of the mechanism that moves the needles. It allows transition away from having to fabricate 
extremely small features and deliver a wide variety of hemostatics. The primary drawback of this is how 
to develop a mechanism that can reliably perform this task in less than 1 second. 
 
 
5.0 CONCEPT SELECTION PROCESS 
 
In order to select the best process, a quantitative analysis was used to compare all of the concepts to each 
other. From this data, the best concept was selected and then slightly modified so that all of the design 
criteria were maximized. In the previous section, the main advantages and disadvantages were described 
for each of the main concepts. This section will discuss how those advantages and disadvantages factored 
into the selection process. 
 
Pugh chart: The method that was chosen to show the quantitative analysis that was performed to select 
the best concept was the Pugh chart. The Pugh chart, which is shown in Table 2, compares all the 
concepts to each other with respect to the selection criteria, which are the top seven costumer 
requirements. The weight of the selection criteria is the weight of the customer requirements divided by 
ten for more reasonable analysis. The rating that each concept received was a number from one to five, 




Table 2: Pugh Chart
 
 
From the Pugh chart above, it is clear that concept 3 is the best concept. This concept offers the best 
performance in all of the selection criteria. The criteria in which it out performs the other concepts the 
most is reliability (testable prototype), because it is the only concept that can be feasibly manufactured 
(although still difficult because of the small scale of the needle). This concept enables the deployment of a 
hemostatic, and the easy removal of tissue from the kidney. These are the two main functions from the 
functional decomposition. It also accomplishes all of the sub-functions, and does not alter current medical 
practice. After analyzing of the results from our Pugh chart, the advantages and disadvantages of all the 
concepts, it was obvious that concept 3 was the best concept for this project.  
 
Concept 3 also provides the best chance of accomplishing all of our engineering specifications, included 
needle volume, tissue cavity volume, needle velocities, and deployment of the hemostatic agent. The main 
difference between this concept and the others is that it allows the tissue cavity volume to be much 
greater, which is very important because it enables the doctor to get an adequate sample and greatly 
improves the reliability of the device (a major costumer requirement). 
 
The only changes to the concept were due to the fact that it did not score perfectly. Thus, some changes 
were made to it in the alpha prototype phase. The most important change is the removal of the channel in 
the outer needle. This change was made to make the device easier to manufacture and make it more 
reliable. Even with this change, concept 3 will still be very difficult to manufacture, which will be the 




6.0 NEEDLE DESIGN 
  
After revising the engineering specifications thoroughly, The main needle design challenge is to come up 
with a way to deploy hemostatic agent in a confined inner needle geometry. Thus, the main focus is on 
the inner needle design. A design was needed that had an inner needle that will deliver the hemostatic 
agent and collect the tissue sample at the same time. The alpha design will have the same tissue collecting 
sample site size and similar needle tip geometry (cutting angle) as the Bard® Monopty® biopsy device. 





Figure 9: A zoom out picutre of the inner needle geometry. 
 
It was decided to construct a channel underneath the inner needle in order to deliver the hemostatic agent 
during biopsy. (Figure 10) The semicircle channel functions as a smooth guide for the hemostatic agent 




Figure 10: Hemostatic agent travel channel 
 
The needle design collects tissue sample via trapping and cutting the tissue sample in the tissue collecting 
site. The kidney tissue will quickly extend or fill up the tissue collecting site in this step. The sharp edges 
of the outer needle will cut through the tissue that stays in the tissue collecting site. Finally, the 
hemostatic agent is deployed. The duration between needle firing should be fast enough to minimize the 
injury on the kidney. The hemostatic agent will quickly fill up the wound cavity and react with the blood 





Channel and hemostatic 




Figure 11: Inner needle was injected into the kidney 
 
 
Figure 12: Outer needle is fired up and cut through the tissue that stays in the tissue collecting site. 
 
 
Figure 13: Hemostatic agent is released and quickly reacts and fills up the wound in the kidney. 
 
 
7.0 ALPHA DESIGN 
  
7.1 Engineering and Parameter Analysis  
To develop a new biopsy needle capable of delivering a hemostatic to the biopsy site primarily concern is 
with areas of the mechanical engineering undergraduate curriculum. In the product design statics and 
mechanics of materials, dynamics, and fluid dynamics must be considered. Since the design is not 
predicated on the transfer of thermal energy, thermal sciences may largely be ignored. At this time the 
current alpha prototype is envisioned as spring loaded disposable device that has very few operation 








expected performance of the current alpha prototype the changes to the prototype may require the device 
to become an “investment” piece of hardware where material failure modes must be considered. 
Additionally, it is assumed that simple dynamics suffice to generate the proper response of the system. 
However, test and design modifications may require to better model the system and consider the system 
response to the applied forces. 
 
Statics Problems: Simple static analyses of parts experiencing large forces or that have attachment 
conditions will be performed. To accomplish this the use of free body diagrams to identify forces and then 
determine resultant forces at critical loading points was implemented. 
 
Stiffness of Beam Problems: In the course of designing the new biopsy needle geometry, the current 
stiffness of the BARD Monopty® biopsy device’s inner needle must be maintained. The fact that the 













Figure 14: Force Diagram 
 
From the cross-section view above the second moment of areas Ix and Iy can be determined and Ixy can be 
neglected due to symmetry. Using Equation 1 the maximum stress σzz can be determined. Assuming 










      (Eq. 2) 
 
The σzz determined from the Monopty® inner needle design for the load then can be used to back-
calculate the necessary needle dimensions to maintain stiffness. The use of the parallel axis theorem can 
accomplish this. To limit the equations to generate a singular solution and not a matrix of solution the 
width and depth of the channel required to deliver the hemostatic must be determined. 
 
Channel Design Flat Design 
 
Figure 15:  Potential Inner Needle Geometries 
 




The flat design may be approximated as a simple rectangular or trapezoidal cross-section for analysis. The 
channel design will be decomposed in to a rectangular section with two partial circular sections. 
 
This method of analysis may also be used if clips or other compliant mechanisms or attachments are used 
in the biopsy needle mechanism design. However these problems will likely reduce to simple beam 
bending and displacement problems that are based on energy inputs that create the proper motion. 
 
System Energy and Dynamics: To meet the benchmarked targets for needle velocities, simple rigid 
body dynamics and Newton’s Laws are applied. Where “m” is the mass of the needle and attached 
components and “a” is the acceleration required to meet the velocity requirements in the given 
firing/insertion distance of the inner and outer needles. The use of energy methods, K.E.=.5mv2, if energy 
is stored in the mechanism. At this time the effects of tissue interaction and friction in system are 
neglected by providing a performance factor to the calculated requirements (ie. force, acceleration, 
velocity). 
 
Fluid Dynamics: In the flow of a hemostatic to the biopsy site the appropriate steady state mass/volume 
flow rate of the incompressible fluid hemostatic agent must be determined. Once determined the required 
flow rate of the hemostatic agent can be used to determine the appropriate pressure to apply to the fluid 
flow. This is a function of backpressure, viscosity, and delivery path geometry. 
 
The flow rate will be determined at this time by the fact that the hemostatic agent must fill the volume of 
space being vacated during needle retraction. From this volume flow rate Bernoulli’s equation can be 
used to solve the necessary pressures that apply. Gravity is neglected in this analysis as the fluid is 
moving over a trivial distance. 
 
Bernoulli’s Equation (P = pressure, ρ = density, v = velocity of flow, γ = specific gravity) 
 
𝐶𝑜𝑛𝑠𝑡𝑎𝑛𝑡 𝐴𝑙𝑜𝑛𝑔 𝑆𝑡𝑟𝑒𝑎𝑚𝑙𝑖𝑛𝑒 = 𝑃 + 1
2
𝜌𝑣2 + 𝛾𝑧    (Eq. 3) 
 
Volume Flow rate (Q= Vol. Flow Rate., A= Cross-sectional area, v = velocity of flow) 
 
 
Q=A*v      (Eq. 4) 
 
Pressure Drop (ΔP=Pressure Drop, λ= Friction co-efficient, ρ= density, w = flow velocity) 
 




× 𝑤2      (Eq. 5) 
 
While this analysis should provide appropriate data regarding the necessary design parameters of design, 
validation in an experimental test setup will yield the best drivers for design changes as effects of the 
biopsy process are not entirely understood at this time. Thus, the problem identification and design 
changes will have to be proposed following some initial testing. Manufacturing at this scale also proves to 
be very difficult so the dimensions required to theoretically succeed in this design exercise may prove too 
difficult to create in reality. 
 
Snap Fit/ Bending Problem Analysis: Snap fit mechanism is implemented in our design. The snap fit 
mechanism will enable us to eliminate the need for complex fixtures and to translate linear motion easily. 
In the design, a pair of clips is needed to release the compressed spring when activated by the push 
button. The amount of force needed, deflection of the clips and suitable materials for the clip are the 





Figure 16: Snap fit with parameter 
 
h=height of the clip 
b=base width of the clip 
L=length of the clip 
F=deflection force exerted on the clip 
E= Young’s Modulus of material 
 





      (Eq. 6) 
 





     (Eq. 7) 
 





      (Eq. 8) 
 
Then, plugging in different value of Young’s Modulus into the expression we were able to determine the 
different deflection force needed. The results obtained are shown below: 
 
Table 3: Deflection Force Analysis 
Material Young’s Modulus (Mpa) Deflection Force (lbs) 
Aluminum 6064 69000 37.0 
Delrin  2800 1.5 
 
 
As seen in table, the deflection force needed for Delrin is about twenty times smaller than the force 




fit mechanism will work and also minimize the energy needed to actuate the released mechanism of the 
spring.  
 
Inner Needle Cross Section in Electrical Discharge Machining (EDM) Analysis: The stiffness of the 
inner needle’s tissue collection site is one of the important factors that we need to determine. An electrical 
discharge machining is needed to make the channel for delivering the hemostatic agent and the tissue 
collection site. This machining process will highly affect the stiffness of the needle because the tissue 






Figure 17: Cross section view of the inner needle 
 
To ensure the needle’s stiffness remains the same as the stiffness of the BARD device after making the 
channel underneath, we need to reduce the volume of the tissue collection site. The volume of the tissue 
collection site is determine by y, as shown in figure. The amount of volume reduce is calculated using the 
definition of second moment of area Iy below, 
 
𝐼𝑦 = ∫𝑥𝑦 𝑑𝐴       (Eq. 9) 
 
 
Second moment of area is used here because it affects the stiffness of the needle.  
 
To determine the centroid of the cross section, we measured and get the geometry of the cross section and 
plug it into the definition of centroid,  
 
𝐶 = ∑𝐶𝑖𝐴𝑖∑𝐴𝑖                                                                     (Eq. 10) 
 
Then, using Mathematical to simulate both equations, we determined y to be 0.68mm.  
 
 
Pressure of Hemostatic Deployment Analysis: We used Bernoulli equation to calculate the amount of 
pressure needed to deploy the hemostatic agent into the kidney. Since the prototype is designed to 
accommodate a huge variety of hemostatic agent, we will use a highly viscous hemostatic agent as the 
higher limit for the density of liquid in the equation. Several assumptions were made to simplify the 
calculation; the system is assumed to be in steady state, the liquid is incompressible and there is no 









2 )ρh     (Eq. 11) 
 
 
Ph  : Pressure of Hemostatic Deployment 
Pb : Blood Pressure 
channel for hemostatic 
agent 
tissue collection site y 
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ρh : Hemostatic Density 
ρb : Blood Denisty 
vh : Velocity of deployment 
vb : Velocity of blood flow 
 
From the equation above, we can calculate the force needed, F to create that amount of pressure, Ph, 
 
𝑭 = 𝑃ℎ 
A
     (Eq. 12) 
where A is the area of the E&R plate.  
 
Spring Constant and Needle Velocity: Using the fact that the force exerted by the spring of the BARD 
device is able to cut through the kidney tissue, we obtained the spring constant from a master student, 
Mainak Mitra. From the spring constant K=810.4N/m we calculate the force, F exerted by the BARD 
device to be 17.8N from the equation, 
 
𝐹 = 𝑘𝑥      (Eq. 13) 
where x is the needle displacement. Then, using the same equation and the displacement on our prototype, 
we determine the spring needed. 
 
Safety Factor of Clips: To calculate the safety factor, we used Solidworks Simulation to perform simple 
Finite Element Analysis on the clip to ensure they do not fail.  
 
By applying F=1.5lbs that we calculated earlier on the clips and making the end of the clips fixed, we 







Figure 18: Stress Concentration Plot on the clip 
 









= 2.2   (Eq. 14) 
 
The safety factor of 2.2 is sufficient enough to allow any unexpected loads, misuse, and emergency 
situations. 
 
7.2 Final Design Description  
The final design, as shown in Figure 19, is designed with the engineering specification previously derived 
and with rapid machining in mind. In this section we will break down the device into major component 
sections with sub-parts’ general geometry and function discussed in detail.  
 
 
Figure 19: Final design  
 
Housing Components: The housing is comprised of four unique parts that enclose the mechanical 
function of the device. In short, the house is designed to enclose the mechanical parts of the device while 
leaving the user able to access the vital parts of the biopsy device. Starting at the top of the device, the 
Top Plate is the upper most part of the housing components as shown in Figure 20. The Top Plate is has 
three main geometric features. The plate has four drilled holes that allow assembly to the side housing 
components with ¼ -20 bolts. The next geometric feature is the large center hole. This milled hole is 
designed to allow the release button to protrude the the exterior of the device and allow the user to actuate 
the mechanism. To allow for machining simplicity the hole is square with properly radius corners to allow 
for using a single ¼ end mill bit and provide clearance to the release button. Finally, the exterior 





Figure 20: Housing Components 
 
The two most substantial components of the housing are the side housing components. The housing sides 
provide the most critical components of the housing design. The two sides of the housing comprise the 
two largest parts in the device and have the highest mass in the device. The side house contains the all of 
the moving components and provides stability to the device. It also guides and aligns all of the moving 
components and permits them to translate only in the desired vertical motion. The housing is also 
designed to be the stationary parts on which the springs will exert their reacting force when under 
compression. The exposed slots on the device permit the user to disengage the inner needle to be released 
so that the biopsy specimen can be examined. The housing is also vital in the performance of the 
compliant clips in our design. The housing sides have locations for the clips to engage with the two 
needle pistons and have attachment points for the clips required to retain the retraction plate. The two side 
plates also have ¼-20 taped holes for attachment to the Top Plate and the Bottom Plate. These eight 
bolting location should provide sufficient coupling between all of the housing components. If in the event 
this method of housing assembly is insufficient to maintain proper of internal alignment of the moving 
parts there is sufficient space within the side walls of the housing to allow up to four cross connecting 





Figure 21: Housing system 
  
The Bottom Plate makes up the final component of the housing system for the biopsy device. The plate 
similar to the Top Plate is designed to create a bottom surface for the device as well as provide a surface 
for the 3rd release spring to load on until released. The shape of the Bottom Plate can be seen below along 
with the guide hole for the inner and outer needles. 
 
 
Figure 22: Housing base plate 
 
Release Button:  The release button, shown below, starts the firing process of the biopsy device by 
transferring force from the user to the compliant clips of the inner needle housing causing them to 
elastically deform allowing them to release from the housing surface. The design of the button is such that 
it can quickly be manufactured and modified in the event that difficulty is encountered in with achieving 





Figure 23:  Release button 
 
Inner Needle Piston Components with Compliant Clips:  The Inner Needle Piston with clips is 
comprised of five parts of which four are unique pieces. For the device to function properly, the inner 
needle must be released from its nominal position and translate along the vertical axis to the biopsy 
position. Upon collection of the tissue specimen the needle must be retracted. After returning to the 
nominal position there must be a way to disengage the needle from the spring force and clips to collect 




Figure 24: Piston components 
 
First examining the Inner Needle Piston casing illustrated above, the casing has three critical functions. 
The upper surface of the casing is a point of contact between the 1st release spring and the housing. The 
upper portion of the casing has milled grooves to accept the compliant clips. The threaded 1/8th inch 
through holes provide the means of carrying the load between the clips and casing. The next feature of the 
casing is the ½ inch dia. bored hole from the bottom of the casing. This cavity creates space for the Inner 
Needle Piston carrier as illustrated above. The casing has the square channels to accommodate the arms 
25 
 
from the carrier. The casing’s remaining geometry is driven by stability, packaging constraints, and 
leaving surfaces that will interfere with the lower compliant clips causing them to release. The needle 
carrier featured above on the right may be developed as a single solid component or two simple 
components attached with a screw and it has two simple functions. The first function is to provide and 
attachment point for the inner needle. This is accomplished through a small bored hole for the inner 
needle and the utilization of a set screw to keep the needle in place. The second function is to provide the 
user a way to disengage the inner needle from the casing and reload the retraction plate after firing. 
Finally the clips that attach to the casing hold the spring in compression until being released by the user 
depressing the button. 
 
Outer Needle Piston Components with Compliant Clips:  The Outer Needle Piston Components with 
clips is comprised of two main components. The outer needle casing, shown below, has very similar 
functions to the inner needle casing with a few key differences. 
 
 
Figure 25: Individual Pistons 
 
The casing is the interface between the needles and the hemostatic agent injection point. The housing 
accepts the hemostatic through a hole drilled in the side of the casing that cuts through the outer needle. 
The location of the port for the hemostatic is crucial to hopefully avoid leaks into the device through 
carefully controlled tolerances. The outer needle casing again provides stability and alignment to the 
needles and a place for the 2nd release spring to act against. 
 
Expel and Retraction Plate with clips:  The E&R, show below, is designed as a single component that 





Figure 26: Retraction Plate 
 
The primary function of the plate is to expel the hemostatic from the storage syringe loaded in by the user. 
The secondary function of this plate is to simultaneously retract the outer and inner needle. This 
simultaneous retraction and expelling of the hemostatic is designed to control the rate and timing of the 
hemostatic injection with the retraction of the needles. The E&R plate shown below is guided by tracks in 
the side housing elements of the biopsy device. The device is initiated by the collision of the outer needle 
casing with the compliant clips. The compliant clips retaining the E&R plate are mounted to the housing 
through taped and drilled holes in the housing sides.  
 
Needles:  The biopsy device has two needles. These needles are very similar to those found on the BARD 
Monopty device with one critical exception. The inner needle has a channel machined on the back of 
needle to provide a pathway for the hemostatic to reach the biopsy site. The channel depth was selected 
such that we would achieve minimal losses to stiffness of the inner needle at the biopsy site. The inner 




Figure 27: Needle design 
 
Release Springs:  The biopsy device has three springs that make the device operational. There are two 
springs of stiffness of 4.5lbs/inch that when released from their compressed positions extend 22mm 
causing the translation of the inner needle first and sequentially the outer needle. The third spring is 
considerably stiffer at approximately 27lbs/inch. This high stiffness is a consequence of having to achieve 




Biopsy Device Operating Sequence: 
1. To prime the device the user must first prime the needle channel by forcing hemostatic through it 
so displace the air in the channel reducing the risk of air emboli. 
2. The user must ensure that the Inner Needle is securely in the firing position by visually examining 
that the needle carrier arm is in the front of the device. 
3. The user then must place the desired hemostatic in the firing chamber in a syringe withdrawn to 
the desired length. 
4. The user must then grip the device such that their digits are clear of the external and internal 
moving arms. 
5. The user will then depress the Release Button. 
6. The release button will translate downward the vertical axis of the device due to the force applied 
from the user. 
7. The release button will engage the first set of compliant clips and due to the force applied from 
the user it will cause the clips to deflect due the bending moment caused by the force applied 
through the button. 
8. Upon the clips deflecting sufficiently far enough to clear the clip-housing interface the 
compressed 1st release spring will elongate while applying force to the inner needle casing and 
thus the inner needle carrier and inner needle. This force will accelerate the needle as it translates 
down the vertical axis of the device a distance of 22mm. 
9. At the completion of translation the inner needle casing will interfere with the second set of 
compliant clips to deform from the force applied by the inner needle casing. 
10. As the second set of clips deflects sufficiently far to clear the housing, the 2nd release spring will 
elongate while applying for to the outer needle casing and thus the outer needle. This force from 
the 2nd release spring will accelerate the outer needle as it translates down the vertical axis of the 
device a distance of 22mm. The outer needle will cause tissue local to the biopsy collection site to 
experience sheer forces that will leads to the ultimate tensile failure of the tissue causing it to 
separate from the biopsy tissue. 
11. At the completion of translation of the outer needle casing, the casing will interfere with the E&R 
plate clips causing them to deflect as the other compliant clips had. 
12. After the proper deflection, the 3rd release spring will engage driving the E&R plate up the 
vertical axis of the device causing the 1st and 2nd release spring to compress and returning the 
inner and outer casing back to the nominal positions. It will simultaneously expel the hemostatic 
as the plate will depress the syringe plunger forcing the hemostatic into the needles. 
13. To collect the biopsy specimen the user must rotate the inner needle carrier arm 90 degrees to 
disengage it from the inner needle casing and then depress the E&R plate so as to reload the 
mechanism while simultaneously providing access to the biopsy tissue. 
 





Figure 28: Firing Sequence 
 
 
Figure 29: Firing Sequence (cont.) 
 
7.3 Prototype Description  
As discussed earlier, the final design in this project is an experimental, “one off” device being created as a 
laboratory instrument. Therefore, the prototype will not differ greatly from the final design. The prototype 
will be manufactured to be resembled as closely as possible the final design. The purpose of both the final 
and the prototype will be to validate the idea that delivering a hemostatic agent through a biopsy needle is 
an effective way of reducing the risk of bleeding at the biopsy site. Because the final prototype and final 
design are virtually the same, no further description and analysis is provided for the prototype. Following 
this point, they are assumed to be the same. The explanation for the validation of the device is explained 




7.4 Fabrication  
Machining and Materials: For the purposes of this prototype the materials that were used are 6061 
Aluminum and Delrin. These two materials were chosen for ease of fabrication and appropriateness of 
design needs. Because this device is for experimental use the selected materials used in the prototype do 
not need to be used for a mass produced device. The two machining processes that were used are an 
electric discharge machining (EDM) process and a milling process. These two processes removed 
material from the stock acquired to create the individual parts. These two processes were chosen for the 
speed at which the parts can be fabricated. Also, they allow for the appropriate dimensioning necessary 
for each of the parts. Other options were looked at for machining but rapid prototyping and hard grinding 
were determined to have too many issues with the appropriate dimensioning and strength. All of the 
engineering drawings can be found in appendix D. 
 
Inner needle: The fabrication of the inner needle was done using a wire EDM process. Using this process 
a groove of 0.4mm in height was cut away down the length of the needle as shown in Figure 26. 
Specifically, this groove was cut from the tip of the inner needle up to the point where the outer needle 
sheathe is secured into its piston. This process was chosen because it provides the best option for 
fabricating the groove dimension needed for this mechanism’s design. A picture of the setup of on the 
EDM machine is shown in figure 30(a).  
 
 
Figure 30 (a): EDM machine setup   (b):Sheet metal tool and custom vice with needle 
 
In order to create the channel, a piece of sheet metal with thickness 0.4mm was used as the “wire,” or the 
tool in the EDM machine. The needle as secured in a custom made vise, which enable the needle to be 
worked on without it bending or deforming in any way. This device was made by taking a piece of 
aluminum and milling a groove with a depth of 1mm for the needle to be placed in, and 2 matching 
smaller pieces to be placed on top of the needle and bolted down to secure the needle which the 
machining was happening. This device can be seen in figure 30(b). 
 
Needle sheathe: The fabrication of the outer needle sheathe was done using a simple cutting process. The 
length was determined by the total length from the needle sheath’s end to the retracted position of the 
needle sheath’s piston. Cutting from the non-cutting end was chosen so that only needle length needs to 
be addressed in the fabrication of this part thereby making sure no process needed to be carried out to re-
fabricate the cutting end of the sheathe.  
 
Inner needle sled:  The inner needle sled was created using aluminum stock. This stock was milled out to 





Inner needle and Needle sheathe pistons: The inner needle and needle sheathe pistons were created 
using aluminum stock. The stock was milled out to create the parts shown on the left side of Figure 24. 
The dimensions of these pistons were set to allow for the springs to be able to move on the outside of 
them forcing the pistons 
 
Retraction plate:  The retraction plate was made out of aluminum and was machined using the water jet 
machine. This enabled precise machining without much user input and a quick turnaround time. The 
water jet machine was very helpful in the later stages of manufacturing since it enabled us to work on 
other critical components while just one person was supervising it. This part was later broken into two 
pieces, the retraction plate bottom and retraction plate top for ease of machining. For details about this 
and all other changes made to the design during manufacturing, please see appendix E 
 
Removable firing clips: The removable firing clips were created in pairs using Delrin®. These pairs 
were created in large quantity to allow for multiple replacements during testing. Therefore, the pairs were 
cut from a long group of the clips. The Delrin® was cut into these groups using a milling process. The 
purpose of this choice is to allow for good compliance of the clips for our firing purposes. The reasoning 
behind creating many of them is both for ease of fabrication and for allowance of testing problems 
associated with clips failing.  
 
Device housing: The outer housing shown in Figure 21 was made from Aluminum. Because of time 
constraints, and the importance of precise machining of these parts, they were outsourced to First Cut, a 
CNC prototype company in Maple Plain, Minnesota. The dimensioning for this part was crucial to allow 
for the motion of the spring and the pistons within itself. The inside surface finish of these parts was also 
crucial to allow for the sliding of the parts within the device.  
 
Assembly Plan 
The assembly of the device was one of the simpler parts of the project. Figure 31 shows all of the parts of 
the device laid out on a table top, including all of the machined parts and all of the purchased parts. Table 





Figure 31: All parts of alpha prototype  
 
Table 4: Key to Figure 31 
Part Number Part Name 
1 Right Housing 
2 Top Plate 
3 Retraction Spring 
4 Outer Needle 
5 Retraction Plate Bottom 
6 Inner needle spring 
7 Out Needle Sled 
8 Retraction Plate Top  
9 Inner Needle(through spring in this picture) 
10 Inner Needle Piston 
11 Inner Needle Sled 
12 Firing Clips 
13 Syringe Adapter 
14 Left Housing 
15 Bottom Plate 
16 Button 
17 Syringe 
18 Outer Needle Spring 
19 Arm 
 
First, attach the firing clips in place in the housing and the inner and outer needle sleds, as they are in 
Figure 31. In order to assemble the device, one must start assembling with the retraction plate top, part 8. 
Place the outer needle spring on top of the outer needle sled, which should already have the outer needle 
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in it. Then take the retraction plate bottom and enclose the sled and the spring within the retraction plate 
top and bottom, with the syringe adapter hole in the outer needle sled facing the same way as the 
protrusion in the retraction plate bottom. Once this is done, place the inner needle in the inner needle 
piston, and insert the inner needle piston in the inner needle sled. Then press the inner needle through the 
whole in the retraction plate top, and through the hole in the outer needle sled. At this point, these parts 
should look as they do in figure 31.   
 
Place this entire unit in the matching slot in the left housing. Then slide the retraction-spring around the 
outer needle and carefully slide the bottom plate around the outer needle and secure the outer plate to the 
left housing with the appropriate screws. Put the button in the matching whole in the top plate, and secure 
the top plate to the left housing using the appropriate screws.  Once this is complete, place the inner-
needle-spring between the inner-needle-sled and the button, as shown in figure 32. At this point, the alpha 
prototype should look like figure 32, with the only step remaining being to simple place the right house 
on top of the left house and secure the top and bottom plates to the right housing. Once this is complete, 
the prototype is fully assembled and should look like figure 33. 
 
 
Figure 32: Alpha prototype assembled but left open 
 
 




7.5 Description of Validation  
In order to test that our device has met all of our engineering specifications, a few steps were taken, first 
ensuring that the device actually works, and then ensuring that the performance is on par with the 
engineering specifications. The table below shows the tests that will be performed in order.  
 
Table 5: List of validation tests conducted 
Step Test Purpose 
1 Testing Setup Determine if testing setup properly simulates kidney 
2 Fire device in air without hemostatic Determine if needles fire in order 
3 Fire device in air with hemostatic Determine hemostatic is delivered through the needle  
4 Fire device into ballistic gel  Determine if device removes “tissue” and clogs a hole  
 
The first step in our testing was to determine if we could achieve a manufactured bleed using our testing 
setup. The setup, shown in figure 34, allowed us to facilitate blood flow through a block of ballistics gel. 
The gel acted as a phantom kidney for our experiment, allowing us to pump water at pressure through 
manufactured cavities which acted as veins for our purposes. The testing setup was successful. We could 




Figure 34: Testing Setup 
 
The next step was to see if the needles fire in sequence, with the inner needle firing first, and then the 
outer needle firing. Because of the mechanics of the device, the only way for the outer needle to fire is for 
the inner needle to fire and release it, so if the outer needle fires when we fire the device, both needles 
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have fired in sequence that step is a success. Unfortunately, due to the non-compliance of the clips, the 
needles would not fire in succession without manually releasing each set of clips. While this was a partial 
failure it still succeeded in its operation with manual firing of its clips. 
 
The third step in this process was to see whether or not the device is able to deliver a hemostatic agent 
through the needle during the biopsy process. This was accomplished by loading the device with 
hemostatic and firing it as would be done in a biopsy procedure, but into the air instead of into a solid. 
This makes it easy to see whether or not some hemostatic is coming out, and because there was not any 
blood pressure at the tip of the needle, the device is less likely to fail than if it were fired into a solid. This 
was a successful test and a picture is shown below. 
 
 
Figure 35: Delivering hemostatic 
 
Next a stimulation of a biopsy needle accidentally hitting a vein or an artery during the procedure. A 
block of ballistic gel was fitted with a soft tube running through it. A pump which replicates blood flow 
(both in pressure and a beating stimulation) was hooked up to the tube so that there is essentially an 
artificial vein running through artificial tissue. The device was loaded and fired into the ballistic gel, 
puncturing the tube. The test determined if a piece of ballistic gel was lodged in the tissue cavity and 
removed from the block. This test was successful in that it achieved our goal of removing “tissue” at the 
site of the biopsy. A picture is shown below. 
 
 
Figure 36: Capturing Tissue 
 
If compliance was achieved with clips further tests would be possible. The fifth part of our validation 
process would have been undertaken. This fifth part would be to hook up a bovine kidney to the same 
pump used in step four. This will provide a transfused kidney that the device can be fired into. An ideal 
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result in this test would be to constituent tissue samples (in size) and have no bleeds. However, there is 
really no way of know whether or not bleeds would have resulted from the BARD device, so the results of 
this test will be slightly inclusive in that regard. The main goal of this test is to see whether or not the 





 Design Critiques and Recommendations 
In this section, we will organize a critique of our project into first some global comments on both the 
design and manufacturing of the prototype device. We will then critique the some of the major design 
concepts/systems and then we will discuss individual components and their respective design and 
manufacturing considerations. Finally, we will also critique our validation testing. Following each 
critique section, we will provide recommendations for improvements based upon each critique. Overall 
project recommendations will be address in following major section. 
 
Global Design Commentary:  By examining our design requirements and engineering specifications our 
primary goal was to achieve Bard Monopty biopsy performance and then introducing a haemostatic agent 
at the biopsy site during retraction of the biopsy needles. Bard Monopty performance is defined by device 
size, biopsy sample size, needle velocity, needle size and stiffness, ease of use, status indicator, and 
reliability of operation. These performance characteristic along with the design goal of deploying a 
haemostatic agent at the biopsy site are a mixture of functional requirements and packaging requirements. 
Consequently, our final design required high tolerances parts to function in a minimal amount of space. 
For expediency and ease of manufacturing based upon available resources our components were given 
square or rectangular geometry. In a production device or a device with higher budget a circular device 
would be a more ideal choice. 
 
Global Manufacturing Commentary:  Given the design requirements, we required very accurate and 
high tolerance parts for our design. Additionally, the size of the parts design made manufacturing very 
difficult. Given the budget, facilities, and time available for completion of this project, it proved very 
difficult to achieve the exact specifications of each unique part while remaining on our manufacturing 
schedule. We also developed a manufacturing method for our needle channel design using an EDM 
machine. This fabrication process required experimentation to determine the best methodology to achieve 
the desired feature on the needle.  
 
Spring-Compliant-Clip Concept/Systems Critique:  The spring and compliant clip design we had is a 
valid method storing and releasing energy in a sequential manner. It is cheap and reliable method of firing 
the needles. This system can easily be disposed of or sterilized for future use. However, this system has 
its drawbacks. It requires that all of the parts fit well together and that every component is functioning as 
designed. It also does not allow for adjustability in the sense that new springs and housing clearances 
need modified to swap out for off the shelf springs. Designing clips that release as required also requires 
significant engineering and even some trial and error. 
 
Spring-Compliant-Clip Concept/Systems Recommendations:  For truly global markets this is the most 
promising and cheapest method of achieving a biopsy and deploying a haemostatic. Springs are also 
extremely compact, which makes them ideal for a hand held hand powered device. We would recommend 
that after careful selection of a haemostatic and gaining knowledge about the interactions between the 





Haemostatic Delivery Concept/Systems Critique:  The concept of delivering the haemostatic down a 
channel located on the back of the needle is a novel way to help control biopsy bleeds. Of the methods of 
delivering a haemostatic to the biopsy site while the inner needle is still present in the outer needle, we 
feel this has the most promise. We had difficulty achieving robust seals to deliver the haemostatic. Other 
methods of creating space for haemostatic deployment may be possible with clever mechanism design.  
 
Haemostatic Delivery Concept/Systems Recommendations:  This concept of haemostatic delivery 
shows promise. However, a robust examination of the possibility of removing the inner needle after the 
sample is collected while the outer needle remains in place is required. Also new biopsy needle designs 
should merit further exploration as they may provide additional pathways for the haemostatic to flow. 
Given the development time of ME 450 deviations from the BARD design proved too risky to explore 
given other design challenges. 
 
Inner Needle with Channel Critique:  The concept of delivering the haemostatic down a channel 
located on the back of the needle is a novel way to help control biopsy bleeds. It allows us to maintain 
most of the biopsy needle stiffness at the biopsy collection site and overall volume of the biopsy 
collection site. The major drawbacks to this method of delivery are the extremely small space allocated to 
the flow of a haemostatic or a working fluid to eject a solid haemostatic at the needle tip. Additionally 
manufacturing of this channel proved extremely difficult. 
 
Inner Needle with Channel Recommendations:  To further refine this design, a true optimization of the 
needle channel size as compared to the stiffness of needle at the biopsy sample site and the size of the 
biopsy collected must be performed. Additional manufacturing methods must be examined to determine 
the optimum channel making technique that results in the best surface finish to facilitate flow. For 
EDMing of the channel a method must be developed to better control uniform channel depth straightness. 
Additional channels or varying channel depths or widths should be further examined. 
 
Retractions Concept/Systems Critique:  Our spring loaded retraction concept shows a method of a 
controlled retraction of the needles and expelling a haemostatic as the needles exit the biopsy site. The 
major drawback is the very large force required to accomplish this. The retraction spring when 
compressed has exerted a force of approximate 40lbs. This force proves extremely hard to load to the 
spring and the vibrations from the violent retraction may have unforeseen consequences. 
 
Retraction Concept/Systems Recommendations:  For a non-externally powered device, this spring is 
the only method of achieving a controlled needle retraction and deployment of haemostatic. In our device 
the retraction method reloads the device and that requires a very stiff spring. In the previous device the 
needles and haemostatic were retracted but the device had to be taken apart to reload it. This design is 
more likely to be successful in the clinical setting if a novel way of accessing the needles is achieved as 
well as a simpler method of reloading the device. 
 
Release Button Critique:  The release button was designed to extend out from the housing of the device 
as to provide the user with adequate clearance to depress the button. The button has a traverse distance of 
1/8th in. to release the clips to Trocar needle carrier. Our design made the button square for ease of 
manufacturing. However, the engagement surface at the bottom of the button was machined with the 
designed geometry to create a right angle at the clip engagement point. This design was flawed as the 
force from the user depressing the button caused a binding condition with the release clips instead of 
displacing the clips allowing them to release. Our manufacturing process did meet the necessary 
tolerances for the clip engagement portion of the button thus causing insufficient displacement of the clips 




Release Button Recommendations:  Most critically, the button clip interference must be redesigned to 
cause the button release and not bind on the release clips.  A simple way to avoid a binding condition 
would be to provide additional clearance for the deflection of the clip as the button engages as well as 
adding a chamfer, a mirror the chamfer used on the clip mirrored about an axis parallel to the interference 
surface, to the button interference surface to avoid creating a point load. Additionally, the protrusion 
length of could be reduced for increased aesthetics and reducing the devices overall length. A new button 
may also move to a rounded geometry as to reduce any sharp points on the button surface. A new button 
design may include a return feature such as a spring or an elastic region material that will return to its 
nominal shape after deformation.   A newly manufactured button must be manufactured to the drawing’s 
specifications and most critically the interference condition at the clip button interface.   
 
Release Clip Critique:  Our release clip design was based upon the idea that with adequate interference 
and applied force that the compliant clips would release each subsequent stage in the biopsy device. The 
clips were designed to be replaced in the device should they fail or fail to perform as expected. This idea 
was good as it will allow further trouble shooting of the device in the future. The material we used to 
manufacture the clips was also had a higher modulus of elasticity resulting in the thickness of the clips to 
be manually be reduced along with an un anticipated lack of force being applied by the releasing feature. 
We also questioned the reliability of the compliant clips and chose to use four clips to retain each stage 
prior to release. While this decision was based upon safety and reliability of retaining the loaded device, it 
also proved to provide additional points of failure in the release of the device. This along with imperfect 
manufacturing caused the clips not to perform to the desired design.  
 
Release Clip Recommendation:  To improve clip performance, a future re-design should aim to improve 
the performance of each individual clip while attempting to reduce the overall number of clips as that 
reduced the number of failure points.  To re-design these clips, one should consider the tensile force 
applied to each clip and the bending moment applied by the reaction force at the holding surface. The 
moment on the parts holding the clips should be calculated so as to ensure that the spring loaded parts so 
not bind in the slot. The interference face angle should be adjusted to reduce the likelihood of a binding 
condition so a slip condition occurs at the surface. Additionally the holding surface area of each clip 
should be minimized to as to facilitate ease of release. However, this minimization of surface area will 
cause the friction between the surfaces to rise because of increased normal forces applied by the spring 
that this relationship must be optimized. 
 
Needle Firing Springs Critique:  The springs used to fire our needles provided adequate force and 
energy storing capability. Our springs were 33% stiffer than the previous teams. The major downfall of 
our spring selection was that we were unable to buy springs to our exact specifications. Consequently, we 
bought spring that we were forced to cut, stretch, and grind to achieve our desired performance. Due to 
fact the springs in compression were not always stable because of manufacturing and seating in the device 
the springs did not compress perfectly vertically. While we did not validate the needle velocity because of 
overall performance problems, we feel confident that if improved manufacturing methods were used 
friction would be reduced and the springs would perform to specification.  
 
Needle Firing Springs Recommendations:  Ideally, custom cut and ground spring of the right stiffness 
and length and compression length could be purchased. Additionally, as a modification of the parts 
directly on either end of the spring could be either attached, perhaps via weld or screws, or at the very 
least have a seat ground for the spring. To improve stability of the spring in compression if improved 
manufacturing of the spring is insufficient, a small solid rod could be placed in the center of the spring 
attached to the holding surface to keep the spring aligned. 
 
Inner Needle (Trocar) Carrier Critique:  Our square inner needle carrier had several good design 
aspects. First, the ability to swap in and out different clip designs or new clips if they break allows the 
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device to be usable beyond the life or design of each clip. The needle carrier also allow the needle sled to 
have a slip fit condition with the inner needle sled that required no physical attachment between the two 
as the inner needle sled cylinder fit within the cylindrical bore. As with the release button the interference 
and forces between the carrier and the subsequent release clips cause a bind to occur.  
 
Inner Needle (Trocar) Carrier Recommendations:  Along with accurate machining of the final part 
within tolerances, the interference between the release clips must be redesigned to ensure the clips will 
release when the device is fired. The needle carrier should also have a seat specifically machined to 
ensure a proper alignment of the spring. Additionally this part needs to have the anterior arm bar path  
 
Inner Needle Sled Critique:  The inner needle sled functioned as designed. It fit with the inner needle 
carrier and was able to hold the inner needle. The milled groove for the arm bar also performed as 
specified and it allowed us disengage the inner needle. 
 
Inner Needle Sled Recommendations:  A redesign of this part should include a better attachment 
method to the arm bar. Currently, a slip fit is all that holds the needle. A magnet or a screw attachment is 
desirable. Additionally, the needle sled should attempt to increase the area of its base to increase stability 
for reloading the retraction spring. 
 
Outer Needle (Cannula) Needle and Needle Sled Critique:  The outer needle was a direct design copy 
of that found on the BARD device. As such, it requires no further redesign. However the outer needle 
carrier block was a novel design. During validation testing we showed that it was possible to port a 
haemostatic into the block and pass it down the back side of the needle. The method of sealing the 
haemostatic in the block by creating a high tolerance fit between the inner and outer need was insufficient 
to direct the majority of the haemostatic flow to the base of the needle. 
 
Outer Needle (Cannula) Needle and Needle Sled Recommendations:  The block concept is one viable 
method introducing the haemostatic to the channel. However, if this method is reused in future designs, a 
better sealing method must be used. Likely a piston with o-rings will be required to create a more robust 
seal. Additionally the needle groove must be further refined to reduce flow resistance. The current flow 
connect also largely obstructs the haemostatic deployment arm which should be redesigned to make a 
more accessible site to load the haemostatic. An alternative method of delivering the haemostatic would 
be to use a compressible tube between the inner needle and outer needle similar to the neck of a flexible 
straw. 
 
Retraction Plate and Spring Critique:  The design of the retraction plate and spring shows promise. 
During validation we were unable to fully test its viability as the retaining clips lacked sufficient strength 
to retain the fully compressed retraction spring. The spring was of the correct stiffness to accomplish the 
desired retraction. In hindsight, the spring is not a feasible means of retraction in its current design. A 
secondary mechanism must be constructed to give the user sufficient force to re-compress the spring. 
 
Retraction Plate and Spring Recommendations:  Retracting the needles is a necessary part design, as 
we must control the timing and location of the haemostatic deployment. In spring powered designs, a 
design consideration must weigh the decision between having a secondary mechanism to reload the 
device or to disengage the needles from the driver springs and retract the needle and deploy the 
haemostatic. In non-spring powered versions of this device, any number of methods may be employed to 
retract the needles and deploy the haemostatic. 
 
Validation Testing Critique:  Our validation set-up provided a unique way to validate our biopsy 
device. It allowed use to validate the ability to biopsy a ballistics gel specimen and guarantee that a bleed 
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will occur when a biopsy is completed. It also avoids having to use a bovine kidney model. This test set-
up also allows the user to tune the ballistic gel veins to simulate a wide variety of flow conditions. 
 
Validation Testing Recommendations:  We recommend that this set-up be maintained. It provides a 
repeatable and reliable way to test biopsy devices. The biggest change is not so much on the device but on 





Our recommendations are broken down into two major sections:  Those recommendations specific to our 
device not previously discussed in the previous section and those recommendations pertaining to the 
overall project goal of developing a biopsy device able to deliver a haemostatic at the biopsy site. The 
recommendations that are device specific are meant to be areas of improvement that should our device be 
a model for future designs, that these additions will help it arrive in the clinic sooner. We also felt it was 
important to discuss how a rigorous research and development process might go to yield a highly 
successful clinical device. This was done because both our device and the previous device have not 
resulted in highly usable devices. 
 
9.1 Device Specific  
These recommendations are based upon the goals of our project. Therefore, they are not all inclusive to 
all future design attempts for a clinical device. Recommendations on the general project goal of to how to 
achieve a clinical grade device are located in the project section below. 
 
Improved User Feedback:  Our device currently has only the arm bar on the needle sled to indicate that 
the device is loaded and has fired. Additional means of determining that all of the subcomponents and 
systems are fully ready and functional on the device should be developed to indicate to the user that the 
device is functioning as desired. 
 
Reloading Mechanism:  Conceptually our device’s reloading mechanism worked. We did have a method 
for loading in new needles and reloading a variety of haemostatic agents. However, this area still requires 
some further refinement. The method of disengaging the needles was awkward and it was almost 
impossible to compress the retraction spring. An auxiliary device should be considered to reload the 
device and disengage the needle between each biopsy. 
 
9.2 Project R&D  
This project is extremely complex. The following is a suggested list of experiments and research 
that could help improve future designs and optimize current design ideas. This overview level 
design of experiments assumes that time and budget are no object, but rather we wanted to focus 
on how an extensive R&D process could be carried out to design the ideal device. Each research 
topic/experiment would require further development and design. These experiments may also 
lead unforeseen new experiments. Conceivably, each experiment could be carried out in the 
course of a semester as part of any number of mechanical engineering curriculum classes. 
 
Biopsy Needle Geometry Experimentation:  This exercise is designed to prove potential alternative 
biopsy collection methods. Alternative biopsy needle designs can be validated on bovine or chicken 
breast model. Validation will come from viability of sample collected for pathological analysis and forces 
required to obtain sample. Other considerations should include damage to surround tissue and needle size. 
During this experimentation, manufacturing considerations should be addressed as well as how 
haemostatic (execution not required) could be delivered given specific needle geometry. For example, in 
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our project we attempted to keep the BARD needle design. To deploy a haemostatic based on that design, 
we had two major choices:  A channel or hole bored down the trocar needle or to remove the needle 
entirely and use the cannula as a pathway to deliver the haemostatic. All needles should be benchmarked 
against the BARD Monopty® device. 
 
Biopsy Bleed Characterization Research:  To improve the phantom test set-up, an analysis of a 
potential range pressures and flow rates of bleeds should be conducted in concert with a nephrologists or 
surgeon. This refinement of data will allow the phantom test set-up to be scaled or tuned to more 
realistically represent bleeding characteristics. This characterization is crucial as it will later influence 
haemostatic selection research. 
 
Needle Size Selection Research:  Examine, using bovine kidney model, the likelihood of biopsy bleed 
based upon needle size. For example, how much does the risk of a bleed increase based upon needle size. 
Given the tight space requirements, it is desirable to maximizing needle size without disproportionately 
increasing the risk of biopsy bleed or other medical complications (infection, damage to surrounding 
tissue, kidney damage from impulse force exerted on the kidney, healing time, etc.) not foreseen by 
increasing needle size.  
 
Haemostatic Selection Research:  Using the phantom kidney set-up determine which haemostatic has 
the highest probability of causing haemostasis given a range of kidney pressures and needle track sizes. 
This testing should consider form of the haemostatic and “acceptable” combinations of haemostatics. This 
testing should be carried out with standard hollow needles. A method of capturing emboli that might form 
as a consequence of haemostatic deployment should be set up to allow a risk assessment of the 
haemostatic causing “floating” emboli. The focus should be on volume of haemostatic required 
normalized to characteristics of the needle track (length, diameter, volume). From the volume data, tables 
of injection rates can be compiled based upon diameter of needle and desired injection time using. 
Additionally, a threshold for maximum volume flow rate can be determined as the point where the 
working fluid would cause tissue damage (think like a water jet). Once establishing the necessary volume 
of haemostatic required to stop a bleed, it should be checked for biological and toxicity problems with 
consultation from a physician. Finally, standard electro-embolization or cauterization should be evaluated 
as a methodology of achieving haemostasis by examining the estimated time required. Again here, local 
tissue damage should be assessed as a consequence of this method of achieving haemostasis. All 
haemostatics need scored in a QFD diagram with other considerations such as price, availability, easy of 
storage, shelf life etc.  
 
Needle/Deployment Optimization Research:  Based upon the four previous experiments, design and 
build a testing fixture capable of testing different combinations of feasible haemostatics and biopsy needle 
designs. This test set-up should focus evaluating and validating both the haemostatic deployment and the 
ability of the needle to collect a biopsy sample. Size of the mechanism and power resources should not be 
a factor. This experimentation should include both bovine and chicken breast models as well as the 
ballistic gel phantom. The results of this research should help future designers understand problems with 
delivering the haemostatic to and through the needles as well as experimentally determine/verify tissue-
needle-haemostatic interactions. It will also serve as test platform for mechanism design. 
 
Device Design I:  At this point, the design of the device should focus improving the testing fixture to 
allow for rapid reload and biopsy ability. Sterilization, environmental impact, and cost for markets should 
start to be considered. While the fixture was originally designed for data collection and idea validation, it 
should now be used as a test bench for different mechanism components given that design of how the 
biopsy is obtained and how the haemostatic is deployed should largely be resolved or at the very least 
optimized from the previous research. Packaging and weight at this point should not be a consideration. 




Device Design II & III:  In this final stage of device development, all of the sub-components and 
systems should have been validated. The goal of this project phase should be to package all of the 
working components and consider what a clinical version of the device might look like. Any 
modifications of previously tested sub-systems can be carried out on the test set-up. In the context of ME 
450, a first prototype should be completed by DR3 so troubleshooting can occur before design expo. 
Device design iteration three should take knowledge gained from final product of first full design attempt 
and make any further modifications necessary to develop a clinical grade device. Any major design 
changes can quickly be validated on the test bench set-up from the needle optimization research or on the 
previous first attempt at a clinical device. These device iterations should result in a product capable of 





Since bleeding is a common risk in the kidney biopsy procedure, Dr. Weitzel has requested our team to 
develop a novel experimental biopsy device that can control bleeding from the biopsy site. The design 
process for the biopsy needle is completed and an alpha prototype has been developed. This alpha 
prototype will enable the delivery of a liquid hemostatic agent down the needle of the biopsy device and 
will help lessen the chance of internal bleeding during the biopsy procedure. It is the opinion of this group 
that with the recommendations presented and design critiques realized a re-completed prototype would 
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APPENDIX B – Description of Engineering Changes 
 
Our device underwent no major design changes in terms of drastically new part geometry or material. 
Most of our design changes were a function of manufacturing processes to simplify machining and 
decrease machine time. Several parts have multiple drawings that are custom made for water jetting or 
milling. In the subsequent sections, I will outline the changes that occurred from the DR3 CAD model. 
 
Inner Corner Radii Added:  Both halves of the outer housing had radii added to the internal corner to 
primarily to simplify machining. The housing halves were designed to be milled using a 3/8in. end mill 
for all major features and a 1/8th in. end mill for any smaller features. The top plate of the device had radii 
around the button hole for ease of machining using a 1/4in. end mill. 
 
Manual Clip Modification:  The clip thickness was reduced by approximately 50% during trouble 
shooting of the device to increase compliance. This note was not a design change, but was mentioned in 
the discussion and recommendations part of the report 
 
Addition of Spring Seat:  An end-milled recess was added to the Inner Needle Carrier part between the 
clips on the top of the part to aid in spring seating 
 
Upper Cannula Addition to Outer Needle Sled:  A .75in segment was added to the top of the Outer 
needle sled to attempt to reduce undesired flow from the Outer Needle Sled. Additionally, epoxy was 
used to secure cannula portions to the outer needle sled. 
 
Needle guide holes added:  Two needle guide holes of 1/8th in. were added to the center of the retraction 
plate to facilitate needles passing through them. This was an oversight from the DR Drawings 
 
Most of the design changes we implemented were subtle and for the sake of manufacturing. Further 
design changes based upon thorough analysis of the device are located in the Discussion and 
Recommendations sections of the report. 
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 APPENDIX C – Design Analysis 
 
C.1 Material Selections 
In the design of our prototype we must consider the nature of the materials we use in the project. When 
choosing the appropriate materials for our device we consider the functions, objective and the constraints 
of the components. One of our major components is the housing. It will be used to hold the spring 
mechanism that fires the inner and outer needle and also to deploy hemostatic agents. The casing has to 
be strong enough to withstand the feedback force applied by the three compression springs during the 
firing sequences. From the engineering analysis of the springs, minimum yield strength of 100 ksi is 
sufficient enough for this purpose. Also, since one of the customer requirements for the device is light 
weight, a low density material is needed for this purpose. We set the density of the materials with a 
minimum value of 0.1 lb/in3. Besides, we also reduce the cost of the materials used by setting a  
maximum price of 50USD/lb. Inserting the parameters identified above into the CES software, we plot 
the yield strength vs. density graph (figure XX). There are many metals that fall into our specifications 
and we identify the top five materials choices are Copper-10% niobium composite, low alloy steel AISI 
5046, Nickel-Mo-Cr alloy, Stainless steel Al 29-4C wrought, and Aluminum 6013.  
 
 
Figure C1: The top five materials choices are circles that are black in color. 
 
From the top five choices, we determined the aluminum 6013 is the best choice for the casing. The 
selection of an aluminum alloy that combines the desire strength to weight ratio will make the device light 
enough to operate easily. Also, aluminum alloy can be easily machined in our in house facilities 
compared to the other four materials.  The features can increase the turnaround of prototype production. 
Also, aluminum will not create hazardous fume when machined unlike the stainless steel Al 29-4C 
wrought.  
 
Another major component in our device is the clips which are responsible for the release mechanism of 
the inner and outer needles. From the engineering analysis, the deflection forces applied on the clips has 
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to be at least 1.5lbs and the material for these clips will has to have a Young’s Modulus of 2800MPa. By 
having the specified Young’s Modulus value, the Delrin will deform under small loads to release the 
mechanism components. Also, for low cost purposes, we limit the maximum cost of the materials used to 
be USD 20/lb. Using the same analysis for the casing, we obtained the Young’s modulus vs. density 
graph (figure XX) and identify five materials that will serve for the clips purposes. The five materials are 
the ABS/PVS (flame retarded), PVC(rigid, lead stabilized), PVC cross-linked foam, Dupont Delrin, and 
PTFE (unfilled). We chose Dupont Delrin for the clips because it fulfill all the specifications that we 




Figure C2: The Dupont Delrin fulfill all of the specifications 
 
C.2 Material Selection Assignment (Environmental Performance) 
The materials that we selected above are not found in SimaPro. Thus, we decided to choose the closest 
materials available which are the Aluminum, primary, at plant/RER S and PVC injection molding. From 
our prototype, we determine the mass of the aluminum needed is about 1kg and the mass of PVC needed 
is approximately 0.1kg.  
Density (lb/in^3)


























Figure C3: Total Mass of Raw materials, air emissions, water emissions, and solid waste for the two 
materials indicated 
 
We calculate the total mass in grams of air emissions, use of raw materials, and (solid) waste from the 
SimaPro software for producing one unit of our device. From the figure, producing 1 kg of aluminum will 
emit more air, waste and solid waste compared to 0.1kg of PVC. However, aluminum required less raw 
materials for production compared to PVC. 
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From the figure above, we conclude that producing aluminum is more hazardous and have a bigger 
impact on the environment. It will release or cause environmental problems that is about a factor of ten 
larger when compared to 0.1 kg of PVC.  
 
Figure C5: Damage meta-categories caused by Aluminum and PVC 
 
From the figure above, the most important damage meta-categories is from the resources. Human health 
might be affected in production but the amount is relatively negligible.  
 
 
Figure C6: Single Score Comparisons in “point” 
 
From the figure above, we concluded that the aluminum production has a higher EcoIndicator 99 “point 
value” on human health, ecosystem quality and resources. It will definitely have a bigger impact when the 
life cycle of the whole product is considered. 
 
C.3 Manufacturing Process Selection Assignment 
Method: Eco-indicator 99 (I) V2.07 /  Europe EI 99 I/I / Normalisation
Comparing 1 kg 'Aluminium, primary, at plant/RER S' with 0.1 kg 'PVC injection moulding E';
Aluminium, primary, at plant/RER S PVC injection moulding E






















Method: Eco-indicator 99 (I) V2.07 /  Europe EI 99 I/I / Single score
Comparing 1 kg 'Aluminium, primary, at plant/RER S' with 0.1 kg 'PVC injection moulding E';
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In a real world, we approximate the production volume to be on the order of thousands. Our device will 
be used by faculty members from universities, medical agencies, and medical technicians from the United 
States and around the world. 
  
The aluminum 6013 that we selected using the CES software will be used in the casing and the two 
housings; the delrin will be used in the clips that release the spring mechanism. In order to mass produce 
our device, we will produce the aluminum by using the casting method. We think that this process is the 
best process in terms of time, effort and cost. By casting the aluminum we will come up with the finest 
finished surface and close tolerance for our device.  
 
For the delrin, we will use injection molding for mass production. The injection molding process is the 
best solution in producing those clips because this process is good in producing small plastic features. 
Since the clips would not tolerate any flaws in manufacturing, the injection molding process will create 
those clips efficiently and precisely. 
 
APPENDIX D – Engineering Drawings 
 






























































































































































APPENDIX H – Calculation of Tissue Volume Displaced when Performing Biopsy 
